• Board of Directors

    Vincent P. Owens
    Chairman CSA Medical Inc.

    Mr. Owens is Managing General Partner and a Founder of Guide Medical Ventures (GMV), an early-stage medical device seed funding and development firm based in Boston. Previously, he was co-Founder and CEO of Intelect Medical, a developer of deep brain stimulation technologies.  He served as President, CEO and Director of the company from its inception in 2005 until 2011 when Intelect Medical was acquired by Boston Scientific (NYSE:BSX).

    Previously, Mr. Owens was founding CEO of Biomec Cardiovascular (BCI), a Minneapolis-based developer of implantable devices for neuromodulation and CRDM.  He led BCI through acquisition by Enpath Medical (NASDAQ:NPTH) in 2003.  Earlier in his career, Mr. Owens held various operations and engineering management roles at Ciba Corning (Siemens) and Circon ACMI (Olympus).

    Mr. Owens serves on the boards of several privately held medical device companies and he is an advisory board member of CCTEC, the technology transfer arm of Weill Cornell Medical College.  Mr. Owens earned a B.S. in Mechanical Engineering from Carnegie Mellon University and an MBA from Ashland University.

    Tara Butler M.D.
    Managing Director Ascension Health Ventures

    Tara Butler came to Ascension Health Ventures (AHV) in 2002 after completing a residency in obstetrics and gynecology at Washington University in St. Louis. She primarily focuses on investments in the medical device and diagnostics sector. Tara has been a board member or observer at several AHV portfolio companies, including Augmenix,  Confluent Surgical, HemoSphere,  ISTO Technologies, MindFrame, Neurolutions, Ocular Therapeutix, PathoGenetix, Stereotaxis (NASD:STXS), and TomoTherapy (NASD:TOMO). Prior to attending medical school, she held positions in business development at Medtronic, in finance at Honeywell and as a laboratory research assistant at the University of Pennsylvania School of Medicine. She holds a BS in Economics and an MBA from the Wharton School of Business at the University of Pennsylvania, and a Doctor of Medicine from the University of Pennsylvania School of Medicine. Tara keeps busy with her three young children, but enjoys skiing and traveling whenever possible.

    Paul LaViolette
    SV Life Sciences

    Paul brings more than 32 years of global medical technology marketing and general management experience. Paul was most recently Chief Operating Officer at Boston Scientific Corporation (BSC), an $8 billion medical device leader. During his 15 years at BSC, he served as COO, Group President, President-Cardiology and President-International as the company grew revenues over 20 times.  Paul integrated two dozen acquisitions and led extensive product development, operations and worldwide commercial organizations. Paul previously held marketing and general management positions at CR Bard, and various marketing roles at Kendall (Covidien). He served on the boards of Cameron Health, Urologix, Percutaneous Valve Technologies and Advamed and currently serves on the boards of CardioFocus, Conceptus, CardioKinetix, CSA Medical, DC Devices, Direct Flow Medical, Thoratec, TransEnterix, TranS1, ValenTx and Medical Device Manufacturers Association (MDMA).  Paul received his BA in Psychology from Fairfield University and his MBA from Boston College.

    Richard Kent M.D.
    Intersouth Partners

    Dr. Kent joined Intersouth Partners in 2008, having previously served as President & CEO of Serenex, Inc., an Intersouth portfolio company that was acquired by Pfizer in April 2008. At Serenex, he managed and grew the company from an early-stage drug discovery company, ultimately directing the company’s acquisition. Prior to his work at Serenex, he served as CEO of Ardent Pharmaceuticals and Senior Vice President, Global Medical Affairs and Chief Medical Officer for GlaxoSmithKline.

    Throughout his career, Dr. Kent supervised dozens of INDs and more than 20 successful NDAs (and equivalent submissions in Europe and the rest of the world) in a wide range of therapeutic areas including CNS, Antivirals, HIV, Respiratory, Gastrointestinal, Anesthesia/Critical Care, Cardiovascular and Oncology. Dr. Kent received his undergraduate degree from the University of California, Berkeley and his medical degree from the University of California, San Diego. He completed his medical training at Harvard (Peter Bent Brigham Hospital), Stanford University Medical Center and Duke University Medical Center, and was a member of Duke University’s medical faculty. He is board certified in both internal medicine and cardiology.

    Tracy Marshbanks Ph. D
    First Analysis

    Tracy Marshbanks is a Managing Director coordinating First Analysis’s research and investing activities in clean-tech & infrastructure as well as leading medical technology investments within healthcare. He specializes in businesses where chemical and life sciences technologies are a key differentiating element. In addition to CSA Medical, Dr. Marshbanks currently serves on the boards of ANI Pharmaceuticals and Cylex Inc. and recently served on the boards of medical technology investments in respiratory and molecular diagnostics. Prior to joining First Analysis in 1999, Dr. Marshbanks held a number of positions with Amoco Corp. ranging from refining R&D to capital planning (first in petroleum refining and then marketing). He earned an MBA from the University of Chicago, a PhD in chemical engineering from Purdue University, and a BS in chemical engineering from Colorado State University.

    Thomas G. Snead Jr
    Blue Heron Capital

    Thomas G. Snead, Jr. is an investor with Blue Heron Capital. He is the retired CEO of WellPoint, Inc.’s southeast region. Prior to Anthem’s merger with Wellpoint Health Networks, he served as president of Anthem’s southeast region. Previously, he was Chairman and CEO of Trigon Healthcare, Inc. He served these Blue Cross Blue Shield organizations for 20 years. Mr. Snead presently serves on the boards of The Child Fund, Virginia Historical Society, VCU School of Business Foundation and the Community Foundation in central Virginia. He has served on the boards of Johns Hopkins Medicine, Riverside Health System and the Virginia Commonwealth University Health System. He graduated with a BS in Accounting from Virginia Commonwealth University.

    Ellen Sheets M.D., MBA
    President and Chief Executive Officer

    Dr. Sheets joined CSA Medical, Inc. in July 2012. She brings to the company a broad range of experience within the medical diagnostic, device and pharmaceutical industries as well as more than 15 years in clinical and academic positions at Brigham and Women’s Hospital/Harvard Medical School. Most recently, Dr. Sheets served as Chief Medical Officer and Vice President of North American R&D at QIAGEN, Inc. where she led a matrixed IVD business team overseeing product development, sales/marketing, clinical trial and constituency relations programs in developing novel diagnostic markers and instrument platforms. Previously, she served as Chief Medical Officer at Predictive Biosciences, where she was instrumental in raising over $45M in venture support. From 2002-2008, Dr. Sheets was Chief Medical Officer at Hologic, Inc. (previously Cytyc Corporation), where she was responsible for medical education, clinical trials, advocacy, government affairs and reimbursement strategies. In this position she directly contributed to identifying and acquiring opportunities that grew top line revenue from $250M to over $750M. She earned Bachelor of Science and Doctor of Medicine degrees from the University of Michigan and a Master’s Degree in Business Administration from New York University.